ASTS
AST SpaceMobile, Inc.
ASTS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
SANG
Sangoma Technologies Corporation
There isn't enough reported data to score SANG yet.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SANG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Under pressure |
SANG's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
SANG PE Valuation
SANG has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
SANG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| -- | |
| Limited | |
| -- |
Analysts expect SANG's losses to shrink, with revenue holding steady.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the stronger earnings trend. Trailing diluted EPS is down 273% for ASTS versus SANG down 400%.
SANG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.15 | +$0.11 |
| Q2 2024 | -$0.26 | +$0.62 |
| Q2 2023 | -$0.88 | +$2.64 |
| Q2 2022 | -$3.52 | -7140% |
| Q2 2021 | $0.05 | -80% |
| Q1 2021 | $0.27 | +17% |
| Q4 2020 | $0.49 | +123% |
| Q3 2020 | $0.29 | 0% |
SANG has swung to a loss: it lost $0.15 per share over the past year, after a profit the year before.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
SANG has the stronger quarterly revenue trend. Revenue is up 187% for ASTS versus up 558% for SANG.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
SANG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2025 | $236.7M | -4.3% |
| Q2 2024 | $247.3M | -2.1% |
| Q2 2023 | $252.5M | +13% |
| Q2 2022 | $224.4M | +524% |
| Q2 2021 | $36M | +82% |
| Q1 2021 | $19.7M | +9.2% |
| Q4 2020 | $19M | +9.6% |
| Q3 2020 | $18.4M | +24% |
SANG's revenue has grown year over year for 21 quarters in a row: $237M last quarter, up 558% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2025 | -2.7% | +0.9 points |
| Q2 2024 | -3.8% | -12 points |
| Q2 2023 | -13% | -23 points |
| Q2 2022 | -47% | -56 points |
| Q2 2021 | -3.6% | -12 points |
| Q1 2021 | 8.4% | -0.3 points |
| Q4 2020 | 10% | +2.8 points |
| Q3 2020 | 9.7% | +3.9 points |
SANG's operating margin was −2.7% last quarter, up 0.9 points from the same quarter a year ago.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
SANG has the stronger cash trend. Its trailing FCF is up 1,063% versus its history, compared with ASTS at down 363%.
SANG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | $39.4M | -1.8% |
| Q2 2024 | $40.1M | +79% |
| Q2 2023 | $22.5M | +17% |
| Q2 2022 | $19.2M | +570% |
| Q2 2021 | $2.9M | -48% |
| Q1 2021 | $1.7M | +83% |
| Q4 2020 | $3.4M | +$5.4M |
| Q3 2020 | $1.7M | +33% |
SANG generated $121M in free cash flow over the past year, more than ten times what it generated the year before.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over SANG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
SANG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +247K shares |
| 1 year | +76% | +14.5M shares |
| 3 years | +331% | +25.7M shares |
| 5 years | +621% | +28.9M shares |
| Available history | +578% | +28.6M shares |
SANG has 33M diluted shares, up 76% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $2.8M |
| Q2 2023 | $559,000 |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SANG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2021 | 2.9x | Moderate |
| Q1 2021 | 4.1x | High |
| Q4 2020 | -1.6x | Net Cash |
| Q3 2020 | -1.7x | Net Cash |
| Q2 2020 | 2.0x | Healthy |
| Q1 2020 | 2.7x | Moderate |
| Q4 2019 | 3.1x | Elevated |
| Q3 2019 | 0.3x | Very low |
SANG's net debt is about 2.9 years of its operating earnings (EBITDA), up from 2.0 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
SANG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 76.3 | Neutral |
SANG's weekly RSI is 61 (neutral) and its Stochastic is 76 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
SANG PE vs Technology Sector
| Metric | SANG | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
SANG has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
SANG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.60 | 3.7% above |
| 20 week MA | $4.18 | 14% above |
| 50 week MA | $4.29 | 11% above |
| 100 week MA | $4.98 | 4.2% below |
| 200 week MA | $4.63 | 3% above |
SANG has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
SANG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.3 | $18.1 | +36% |
| 2021 | $18.1 | $16.7 | -7.7% |
| 2022 | $16.7 | $3.79 | -77% |
| 2023 | $3.79 | $3.20 | -16% |
| 2024 | $3.20 | $7.00 | +119% |
| 2025 | $7.00 | $5.03 | -28% |
| 2026 YTD | $5.03 | $4.77 | -5.2% |
SANG has the edge over ASTS on returns for 2026, with the stronger performance.